What AVITA Medical Doubters Got Wrong Before A 378% Rally

If you had backed AVITA Medical at the start of 2026, the outcome would look very different today. Holding AVITA Medical from the start of the year would have returned 378.1%, including dividends. That headline alone raises a harder question. If you were sitting on the fence then, weighing Medicare reimbursement uncertainty against bullish forecasts for trauma expansion and margin repair, which signals would have mattered most to your decision?

Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.

AVITA Medical is not the only name tied to this theme. Zero in on 35 healthcare AI stocks and compare how each one is priced.

The Argument You Would Have Been Weighing On AVITA Medical

The shares cost US$3.45 at the start of the period, so any call on AVITA Medical hinged on which story you trusted more.

The bullish Narrative pointed to a Fair Value of US$8.26, pegged 139% above the start price. It hinged on revenue growth of 42.5% and profit margins reaching 35.8% within three years.

The bearish view set Fair Value at US$3, only 13% below the start price. It was built around slower 21.2% revenue growth and concern that dependence on RECELL kept business risk high.

What The Results Changed For AVITA Medical

The clearest new fact came from AVITA Medical lifting its 2026 revenue guidance to US$92 million to US$94 million, which leaned toward the argument that demand could support higher sales. Q3 2026 revenue of US$26.114 million and a smaller net loss of US$6.222 million gave bulls another data point, although profitability remained unproven and kept the cautious case alive.

The lesson here is about testable assumptions. If the thesis hinges on reimbursement clarity and margin repair, track revenue guidance changes, reported net margin and loss levels each quarter to see whether the story is actually turning into cash and not just optimism.

What AVITA Medical's Rally Already Assumes

AVITA Medical now trades at US$16.59. The analyst consensus Narrative on Simply Wall St sets its Fair Value below that level and treats a lot of the recent improvement as already recognised in the valuation.

The Narrative leans on broader RECELL platform use, PermeaDerm and Cohealyx economics, and reimbursement clarity. A buyer today has to believe AVITA keeps deepening adoption across underpenetrated burn and trauma accounts without letting operating expenses drift higher.

"The main thing that still has to go right is that AVITA converts its underpenetrated burn and trauma account base into deeper, multi product adoption while keeping operating expenses roughly flat so that revenue growth translates into the operating leverage that management targets."

One Narrative disagrees with today's price. → See where this Narrative says AVITA Medical should trade

Looking One Step Beyond AVITA

AVITA Medical sits in a corner of healthcare where chronic conditions often shape demand. You can look one link away from burns and trauma.

Patients who survive acute injury often still wrestle with long term metabolic or cardiovascular problems. Those needs are being targeted by a different group of therapies.

One large drug maker is building treatments for obesity, diabetes and related diseases using several types of medicines, not just injectables.

It is also working on cancer, immune and brain disorders, plus new genetic approaches. That breadth could matter if chronic illness costs keep rising.

That argument has a Narrative and a number behind it. → See the company one Narrative values 22% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com